150 related articles for article (PubMed ID: 34516013)
1. Proinflammatory CD20
Quendt C; Ochs J; Häusser-Kinzel S; Häusler D; Weber MS
Ann Neurol; 2021 Nov; 90(5):834-839. PubMed ID: 34516013
[TBL] [Abstract][Full Text] [Related]
2. CD11c
El Mahdaoui S; Hansen MM; von Essen MR; Hvalkof VH; Holm Hansen R; Mahler MR; Jennum P; Sellebjerg F; Romme Christensen J
Ann Clin Transl Neurol; 2024 Apr; 11(4):926-937. PubMed ID: 38332555
[TBL] [Abstract][Full Text] [Related]
3. Serum 3-phenyllactic acid level is reduced in benign multiple sclerosis and is associated with effector B cell ratios.
Oezguen N; Yılmaz V; Horvath TD; Akbayir E; Haidacher SJ; Hoch KM; Thapa S; Palacio J; Türkoğlu R; Kürtüncü M; Engevik MA; Versalovic J; Haag AM; Tüzün E
Mult Scler Relat Disord; 2022 Dec; 68():104239. PubMed ID: 36279598
[TBL] [Abstract][Full Text] [Related]
4. The new era of multiple sclerosis therapeutics.
Bakshi R
Neurotherapeutics; 2013 Jan; 10(1):1. PubMed ID: 23238890
[No Abstract] [Full Text] [Related]
5. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
Apostolidis SA; Kakara M; Painter MM; Goel RR; Mathew D; Lenzi K; Rezk A; Patterson KR; Espinoza DA; Kadri JC; Markowitz DM; E Markowitz C; Mexhitaj I; Jacobs D; Babb A; Betts MR; Prak ETL; Weiskopf D; Grifoni A; Lundgreen KA; Gouma S; Sette A; Bates P; Hensley SE; Greenplate AR; Wherry EJ; Li R; Bar-Or A
Nat Med; 2021 Nov; 27(11):1990-2001. PubMed ID: 34522051
[TBL] [Abstract][Full Text] [Related]
6. Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab.
Brill L; Rechtman A; Zveik O; Haham N; Oiknine-Djian E; Wolf DG; Levin N; Raposo C; Vaknin-Dembinsky A
JAMA Neurol; 2021 Dec; 78(12):1510-1514. PubMed ID: 34554197
[TBL] [Abstract][Full Text] [Related]
7. Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome.
Tintore M; Cobo-Calvo A; Carbonell P; Arrambide G; Otero-Romero S; Río J; Tur C; Comabella M; Nos C; Arévalo MJ; Midaglia L; Galán I; Vidal-Jordana A; Castilló J; Rodríguez-Acevedo B; Zabalza de Torres A; Salerno A; Auger C; Sastre-Garriga J; Rovira À; Montalban X
Neurology; 2021 Oct; 97(17):e1641-e1652. PubMed ID: 34521693
[TBL] [Abstract][Full Text] [Related]
8. Comorbidity and persistence of disease-modifying therapy use in relapsing remitting multiple sclerosis.
Parks NE; Andreou P; Marrie RA; Fisk JD; Bhan V; Kirkland SA
Mult Scler Relat Disord; 2021 Nov; 56():103249. PubMed ID: 34517192
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis.
Cellerino M; Boffa G; Lapucci C; Tazza F; Sbragia E; Mancuso E; Bruschi N; Minguzzi S; Ivaldi F; Poirè I; Laroni A; Mancardi G; Capello E; Uccelli A; Novi G; Inglese M
Neurotherapeutics; 2021 Oct; 18(4):2579-2588. PubMed ID: 34553320
[TBL] [Abstract][Full Text] [Related]
10. Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis.
Correale J; Halfon MJ; Jack D; Rubstein A; Villa A
Mult Scler Relat Disord; 2021 Nov; 56():103264. PubMed ID: 34547609
[TBL] [Abstract][Full Text] [Related]
11. T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis.
Cruciani C; Puthenparampil M; Tomas-Ojer P; Jelcic I; Docampo MJ; Planas R; Manogaran P; Opfer R; Wicki C; Reindl M; Jelcic I; Lutterotti A; Martin R; Sospedra M
Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34535569
[TBL] [Abstract][Full Text] [Related]
12. Complement Activation Is a Prominent Feature of MOGAD.
Keller CW; Lopez JA; Wendel EM; Ramanathan S; Gross CC; Klotz L; Reindl M; Dale RC; Wiendl H; Rostásy K; Brilot F; Lünemann JD
Ann Neurol; 2021 Dec; 90(6):976-982. PubMed ID: 34569094
[TBL] [Abstract][Full Text] [Related]
13. Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis.
Grahl S; Bussas M; Wiestler B; Eichinger P; Gaser C; Kirschke J; Zimmer C; Berthele A; Hemmer B; Mühlau M
Neurotherapeutics; 2021 Oct; 18(4):2589-2597. PubMed ID: 34561843
[TBL] [Abstract][Full Text] [Related]
14. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis.
Sriwastava S; Kataria S; Srivastava S; Kazemlou S; Gao S; Wen S; Saber H; Tripathi R; Sheikh Z; Peterson S; Gwinn R; Bernitsas E
J Neuroimmunol; 2021 Nov; 360():577721. PubMed ID: 34547511
[TBL] [Abstract][Full Text] [Related]
15. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T;
CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228
[TBL] [Abstract][Full Text] [Related]
16. Graves' disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis.
Duarte DB; Silva AMD; Freitas C; Cardoso H
Endocr Regul; 2021 Sep; 55(3):169-173. PubMed ID: 34523298
[No Abstract] [Full Text] [Related]
17. Mutations in the John Cunningham virus VP1 gene could predispose to the development of progressive multifocal leukoencephalopathy in multiple sclerosis patients undergoing treatment with natalizumab.
Flores J; Anguiano O; Rivas-Alonso V; González-Conchillos H; Pérez-Saldivar M; Sotelo J; Magaña-Maldonado R; Quiñones S; Corona T; Olivares H; Hernández-González O; Martínez-Palomo A; Treviño I; Ordoñez G
Mult Scler Relat Disord; 2021 Nov; 56():103266. PubMed ID: 34555758
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography in multiple sclerosis - straight to the target.
Bodini B; Tonietto M; Airas L; Stankoff B
Nat Rev Neurol; 2021 Nov; 17(11):663-675. PubMed ID: 34545219
[TBL] [Abstract][Full Text] [Related]
19. Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity.
Sabatino JJ; Mittl K; Rowles W; Mcpolin K; Rajan JV; Zamecnik CR; Dandekar R; Alvarenga BD; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Augusto DG; Alexander J; Hollenbach JA; Wilson MR; Zamvil SS; Bove R
medRxiv; 2021 Sep; ():. PubMed ID: 34580672
[TBL] [Abstract][Full Text] [Related]
20. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
Sormani MP; Inglese M; Schiavetti I; Carmisciano L; Laroni A; Lapucci C; Da Rin G; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
EBioMedicine; 2021 Oct; 72():103581. PubMed ID: 34563483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
